Biogen research and medicine for Alzheimer's Disease
By Kevin on
Biogen research and medicine for Alzheimer's Disease
Biogen is a major biotechnology company working on Alzheimer's disease, a condition that affects memory and thinking skills. Their goal is to slow down memory loss, find better ways to detect Alzheimer's early, and develop more effective treatments.
Biogen is targeting two primary factors contributing to Alzheimer's disease in the brain:
• Amyloid plaques: These are abnormal protein deposits that accumulate between brain cells.
• Tau tangles: These are tangled clumps of a protein called tau that form inside brain cells.
Biogen is trying to tackle these problems with a few different approaches:
• Lecanemab (Leqembi): This medicine reduces amyloid plaques. It's been shown to slow down memory loss a little bit in some people with early Alzheimer's, but it's not a cure and doesn't work the same for everyone.
• Tau treatments: They are also developing an investigational medicine called BIIB113 that aims to prevent tau tangles. This medicine is currently in clinical trials to determine its safety and effectiveness.
• Early detection: Biogen is working with other companies to develop blood tests that can help doctors find Alzheimer's earlier. This could help people get treatment sooner.
More information on Biogen’s research on Alzheimer’s Disease can be found here:
• Video: Understanding Alzheimer’s Disease
• Website: Alzheimer’s Disease
Detailed information about Leqembi (lecanemab), including how it works and patient experiences, can be found here: